Annual Meeting 2012: Three Causes for Optimism in Lung Cancer

feeds has 409 videos Subscribe Here

Description: Dr. David R. Spigel, program director for lung cancer research at the Sarah Cannon Research Institute in Nashville, discusses three early studies that point to better outcomes with molecularly target agents. The first suggests that an approved drug, crizotinib (Xalkori), might be effective in patients with the ROS1 mutation. The others showcase novel agents, introducing the possibility of immunotherapy by targeting PD1 and of benefiting patients with KRAS mutations by adding selumetinib to chemotherapy.
Shared By : feeds
Posted on : 09/21/12
Added : 7 years ago
Category : Other